Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7768

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7768). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907768)

This is a product label with information about the medication. The product is Telerace Tan, which contains 560mg strength and comes in a pack of 120 tablets. The product number is "66375-0".*

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

This is a description of a figure showing the Responder Rate (250% Reduction from Baseline) in Study 1. The figure displays percentages ranging from 5% to 39.6%, with a notable indication that the results are statistically significant versus placebo.*

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

This text provides data on the Responder Rate (250% Reduction from Baseline) in Study 2 during Period A. The percentages of responders in each treatment group are shown, with the noted statistically significant difference against the placebo group. The study compares the placebo group (N=111) with the groups receiving Levetiracetam 1000 mg/day (N=106) and Levetiracetam 2000 mg/day (N=105).*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

The text describes a figure showing responder rates (>50% reduction from baseline) in Study 3. The responder rate for the placebo group (N=104) is 14.4%, while in the group receiving Levetiracetam 3000 mg/day (N=180) it is 39.4%. The difference is statistically significant, showing the effectiveness of Levetiracetam compared to placebo in reducing symptoms.*

FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

This text describes Figure 4 from Study 4, showing the Responder Rate with a 50% reduction from baseline. The percentages for the placebo group were 44.6% and 45%, while for the Levetiracetam group they were 19.6%. The text also mentions that the Levetiracetam group was statistically significant versus the placebo group.*

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

This text provides information about the responder rate for all patients aged 1 month to less than 4 years showing more than a 50% reduction from baseline in Study 5. The data shows the percentage of responders for Placebo and Lovetracatam, with Lovetracatam showing statistically significant results compared to placebo.*

FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

This data presents the Responder Rate (250% reduction from Baseline) in primary generalized tonic-clonic (PGTC) seizure frequency per week in Study 7. The chart shows a comparison between the placebo group (N=84) and the Levetiracetam group (N=79). The Levetiracetam group achieved a statistically significant reduction in seizure frequency compared to the placebo group.*

FDA Label Image

Chemical Structure (Levetiracetam Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.